NOVELION THERAPEUTICS INC - COM NEW (NVLNF)

CUSIP: 67001K202

Q1 2018 13F Holders as of 31 Mar 2018

Type / Class
Equity / COM NEW
Total 13F shares
15,166,361
Share change
+65,560
Total reported value
$53,078,392
Put/Call ratio
68%
Price per share
$3.50
Number of holders
61
Value change
+$316,670
Number of buys
15
Number of sells
34

Quarterly Holders Quick Answers

What is CUSIP 67001K202?
CUSIP 67001K202 identifies NVLNF - NOVELION THERAPEUTICS INC - COM NEW in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of NOVELION THERAPEUTICS INC - COM NEW (NVLNF) as of Q1 2018

As of 31 Mar 2018, NOVELION THERAPEUTICS INC - COM NEW (NVLNF) was held by 61 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 15,166,361 shares. The largest 10 holders included EdgePoint Investment Group Inc., Broadfin Capital, LLC, Stonepine Capital Management, LLC, ARMISTICE CAPITAL, LLC, MORGAN STANLEY, Sarissa Capital Management LP, Healthcare Value Capital, LLC, BlackRock Inc., FMR LLC, and JW Asset Management, LLC. This page lists 61 institutional shareholders reporting positions in this security for the Q1 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.